Success Rate of MAD/OAT for Moderate OSA
For moderate obstructive sleep apnea, mandibular advancement devices achieve a success rate of approximately 75-82%, making them a highly effective treatment option that should be strongly considered as first-line therapy in this population.
Evidence-Based Success Rates
The most recent 2025 Portuguese guideline explicitly recommends oral appliances for patients with mild to moderate OSA, noting that these devices reduce AHI, arousal index, and daytime sleepiness while improving quality of life measures 1.
Specific Success Data by Severity:
Moderate OSA performs exceptionally well:
- 82% success rate in moderate OSA patients (defined as AHI <20 and ≥50% reduction) 2
- 75% success rate in moderate cases using broader criteria 3
- 69% success rate in moderate OSA patients non-adherent to CPAP 4
- 85% improvement in moderate severity cases across treatment groups 5
This consistently demonstrates that moderate OSA is the "sweet spot" for MAD therapy, often outperforming results in both mild and severe categories.
Key Clinical Context
Definition of Success
Success is typically defined as either:
- AHI reduction to <20 events/hour AND ≥50% reduction from baseline, OR
- AHI <10 with ≥50% improvement, OR
- AHI <5 (complete resolution)
The 2025 guideline acknowledges there is no universal consensus on success criteria, but these are the most commonly used thresholds 1.
Comparative Effectiveness
While CPAP remains superior for normalizing respiratory parameters (AHI, oxygen desaturation), MAD and CPAP demonstrate comparable effects on symptoms and quality of life measures including daytime sleepiness, general physical and mental health, and driving performance 1. The critical advantage is that adherence with oral appliances is significantly better than CPAP 1, with nightly use of 6.7 hours versus 5.4 hours for CPAP 6.
Predictors of Success in Moderate OSA
Favorable characteristics (though none are absolute requirements):
- Younger age
- Lower BMI and smaller neck circumference
- Female gender
- Good nasal patency
- Position-dependent OSA
- Lower baseline AHI within the moderate range
Important caveat: The 2025 guideline emphasizes that "none of these factors is essential for successful treatment, which can be achieved in overweight patients and those with more severe disease" 1. This means you should not exclude patients based on these factors alone.
Critical Implementation Points
Device specifications matter: Custom-made, titratable, duo-bloc MADs are strongly preferred over non-custom devices 1. The device must:
- Allow mandibular advancement in ≤1mm increments
- Have ≥5mm protrusive adjustment range
- Be fabricated by qualified dentists with appropriate training
Follow-up is mandatory: The 2015 AASM guideline recommends sleep physicians conduct follow-up sleep testing to confirm treatment efficacy rather than relying on subjective feedback alone 7. Studies show that adjustments based on objective sleep data (PSG or home sleep testing) significantly improve success rates, with one study achieving 76.5% effectiveness through iterative titration 7.
Common Pitfalls to Avoid
Don't rely on symptoms alone - Subjective improvement does not correlate reliably with AHI reduction. Objective sleep testing at 3-6 months is essential 1, 7.
Don't use non-custom devices - Over-the-counter appliances have significantly lower success and adherence rates 1.
Don't skip dental evaluation - Periodontal health, tooth integrity, and occlusal analysis must be assessed before and during treatment to prevent complications 1.
Don't assume failure in higher BMI patients - While lower BMI predicts better outcomes, successful treatment occurs regularly in overweight patients 1.
Real-World Effectiveness
The most recent 2026 multicenter study of 182 DISE-preselected patients with moderate-to-severe OSA showed mean AHI decreased from 24.4 to 7.1 (68.6% reduction), with 75.8% achieving success criteria 8. This real-world data using Level-3 home polygraphy confirms the robust effectiveness of properly fitted and titrated MADs in moderate OSA.